See more : Toho Chemical Industry Company, Limited (4409.T) Income Statement Analysis – Financial Results
Complete financial analysis of Ventas, Inc. (VTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ventas, Inc., a leading company in the REIT – Healthcare Facilities industry within the Real Estate sector.
You may be interested
- Carmell Therapeutics Corporation (CTCX) Income Statement Analysis – Financial Results
- Mithra Pharmaceuticals SA (MITPF) Income Statement Analysis – Financial Results
- National Storm Management, Inc. (NSMG) Income Statement Analysis – Financial Results
- TV Azteca, S.A.B. de C.V. (AZTECACPO.MX) Income Statement Analysis – Financial Results
- King Resources, Inc. (KRFG) Income Statement Analysis – Financial Results
Ventas, Inc. (VTR)
About Ventas, Inc.
Ventas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries: healthcare and real estate. As one of the world's foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population. For more than twenty years, Ventas has followed a successful strategy that endures: combining a high-quality diversified portfolio of properties and capital sources to manage through cycles, working with industry leading partners, and a collaborative and experienced team focused on producing consistent growing cash flows and superior returns on a strong balance sheet, ultimately rewarding Ventas shareholders. As of September 30, 2020, Ventas owned or managed through unconsolidated joint ventures approximately 1,200 properties.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.50B | 4.13B | 3.83B | 3.80B | 3.87B | 3.75B | 3.57B | 3.44B | 3.29B | 3.08B | 2.81B | 2.49B | 1.76B | 1.02B | 931.58M | 929.77M | 771.79M | 418.45M | 324.72M | 232.91M | 205.00M | 196.70M | 204.58M | 242.32M | 233.25M | 149.93M | 3.12B | 2.58B | 2.32B |
| Cost of Revenue | 3.73B | 2.28B | 2.09B | 1.94B | 1.81B | 1.69B | 1.49B | 1.44B | 1.41B | 1.21B | 1.12B | 979.23M | 678.64M | 325.47M | 302.81M | 306.94M | 198.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 770.72M | 1.85B | 1.74B | 1.86B | 2.06B | 2.05B | 2.09B | 2.00B | 1.88B | 1.86B | 1.69B | 1.51B | 1.09B | 691.40M | 628.76M | 622.82M | 573.67M | 418.45M | 324.72M | 232.91M | 205.00M | 196.70M | 204.58M | 242.32M | 233.25M | 149.93M | 3.12B | 2.58B | 2.32B |
| Gross Profit Ratio | 17.14% | 44.71% | 45.44% | 48.89% | 53.25% | 54.85% | 58.41% | 58.12% | 57.09% | 60.59% | 60.22% | 60.60% | 61.55% | 67.99% | 67.49% | 66.99% | 74.33% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | -0.01 | 0.02 | 0.09 | 0.10 | 0.10 | 0.36 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 148.88M | 144.87M | 129.76M | 130.16M | 166.00M | 151.98M | 135.49M | 126.88M | 128.04M | 121.75M | 115.11M | 98.80M | 0.00 | 0.00 | 38.83M | 36.43M | 36.43M | 26.14M | 23.10M | 16.92M | 12.72M | 9.76M | 10.24M | 9.69M | 7.77M | 5.70M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 148.88M | 144.87M | 129.76M | 130.16M | 166.00M | 151.98M | 135.49M | 126.88M | 128.04M | 121.75M | 115.11M | 98.80M | 74.54M | 49.83M | 38.83M | 40.65M | 36.43M | 26.14M | 23.10M | 16.92M | 12.72M | 9.76M | 10.24M | 9.69M | 7.77M | 5.70M | 0.00 | 1.49B | 0.00 |
| Other Expenses | 0.00 | 1.22B | 1.19B | 1.13B | 1.05B | -66.77M | -20.05M | -9.99M | -17.96M | -38.93M | -18.73M | -6.96M | 0.00 | 0.00 | 263.98M | 161.70M | 161.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.94B | 1.36B | 1.32B | 1.26B | 1.21B | 1.07B | 1.02B | 1.03B | 1.02B | 948.66M | 837.07M | 824.78M | 365.13M | 265.22M | 244.49M | 274.35M | 246.12M | 154.55M | 100.61M | 68.50M | 66.64M | 69.49M | 63.27M | 64.03M | 100.66M | 37.97M | 2.79B | 2.53B | 2.32B |
| Cost & Expenses | 3.83B | 3.65B | 3.41B | 3.20B | 3.02B | 2.76B | 2.51B | 2.47B | 2.43B | 2.16B | 1.96B | 1.80B | 1.04B | 590.69M | 547.30M | 581.30M | 444.24M | 154.55M | 100.61M | 68.50M | 66.64M | 69.49M | 63.27M | 64.03M | 100.66M | 37.97M | 2.79B | 2.53B | 2.32B |
| Interest Income | 0.00 | 463.92M | 425.28M | 7.61M | 10.98M | 24.89M | 6.03M | 876.00K | 1.05M | 4.27M | 2.05M | 1.11M | 0.00 | 0.00 | 842.00K | 2.96M | 2.99M | 2.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 574.11M | 467.56M | 440.09M | 469.54M | 451.66M | 442.50M | 448.20M | 419.74M | 367.11M | 376.84M | 334.48M | 293.40M | 236.81M | 178.86M | 176.99M | 203.18M | 204.22M | 136.54M | 0.00 | 0.00 | 80.20M | 86.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.17B | 3.60B | 3.22B | 3.05B | 2.87B | 2.80B | 2.50B | 2.44B | 979.11M | 828.16M | 753.14M | 724.83M | 459.70M | 214.71M | 207.61M | 235.72M | 237.50M | 119.65M | 88.00M | 54.34M | 39.51M | 41.25M | 40.37M | 43.60M | 42.80M | 29.05M | 123.87M | 99.53M | 89.48M |
| EBITDA | 1.83B | 1.65B | 1.60B | 1.72B | 1.93B | 1.80B | 1.95B | 1.95B | 1.81B | 1.70B | 1.59B | 1.42B | 1.00B | 609.50M | 578.87M | 584.19M | 549.60M | 399.04M | 312.11M | 212.99M | 159.19M | 171.07M | 185.09M | 191.26M | 177.93M | 141.01M | 451.07M | 147.54M | 97.84M |
| EBITDA Ratio | 40.71% | 40.00% | 41.91% | 45.40% | 49.95% | 48.04% | 54.49% | 54.57% | 55.19% | 55.40% | 56.54% | 57.07% | 66.91% | 62.96% | 63.54% | 62.83% | 73.21% | 91.96% | 96.60% | 66.25% | 77.65% | 86.97% | 90.47% | 151.09% | 76.29% | 94.05% | 14.48% | 5.72% | 4.21% |
| Operating Income | 665.12M | 454.08M | 389.30M | 592.58M | 865.76M | 861.09M | 622.09M | 556.79M | 834.72M | 875.84M | 835.80M | 693.64M | 51.17M | 52.22M | 208.12M | 145.29M | 126.32M | 125.42M | 100.22M | 87.10M | 119.68M | 129.82M | 144.72M | 322.51M | 135.13M | 111.96M | 327.20M | 48.01M | 8.36M |
| Operating Income Ratio | 14.79% | 11.00% | 10.17% | 15.61% | 22.36% | 22.99% | 17.41% | 16.17% | 25.40% | 28.48% | 29.74% | 27.91% | 2.90% | 5.13% | 22.34% | 15.63% | 16.37% | 29.97% | 30.86% | 37.39% | 58.38% | 66.00% | 70.74% | 133.09% | 57.94% | 74.68% | 10.50% | 1.86% | 0.36% |
| Total Other Income/Expenses | -704.95M | -511.94M | -1.55B | -1.35B | -618.83M | -569.59M | -644.18M | -354.58M | -118.78M | -8.73M | -11.83M | -79.43M | -210.39M | -202.44M | -190.06M | -185.42M | -174.43M | -136.54M | -103.21M | -42.85M | -47.89M | -79.14M | -163.98M | -252.50M | -247.28M | -124.73M | -102.74M | 35.18M | 24.00M |
| Income Before Tax | -39.84M | -57.86M | 61.39M | 344.65M | 382.99M | 376.04M | 584.15M | 522.87M | 350.26M | 448.38M | 478.48M | 298.27M | 330.44M | 227.13M | 194.27M | 145.29M | 120.35M | 130.58M | 120.90M | 100.17M | 96.73M | 50.69M | 54.28M | -61.25M | 42.54M | 55.96M | 224.47M | 83.18M | 32.36M |
| Income Before Tax Ratio | -0.89% | -1.40% | 1.60% | 9.08% | 9.89% | 10.04% | 16.34% | 15.18% | 10.66% | 14.58% | 17.03% | 12.00% | 18.72% | 22.34% | 20.85% | 15.63% | 15.59% | 31.21% | 37.23% | 43.01% | 47.19% | 25.77% | 26.53% | -25.27% | 18.24% | 37.32% | 7.20% | 3.23% | 1.39% |
| Income Tax Expense | -9.54M | -16.93M | 4.83M | -96.53M | -56.31M | -39.95M | -59.80M | -31.34M | -39.28M | -8.73M | -11.83M | -6.28M | -31.14M | 5.20M | -1.72M | -15.89M | -28.04M | 132.47M | 93.53M | 43.52M | -22.91M | -2.20M | 2.69M | 243.75M | 91.30M | 21.15M | 89.34M | 35.18M | 24.00M |
| Net Income | -40.97M | -40.93M | 49.01M | 439.15M | 433.02M | 409.47M | 1.36B | 649.23M | 417.84M | 475.77M | 453.51M | 362.80M | 364.49M | 246.17M | 266.50M | 226.29M | 282.32M | 131.43M | 130.58M | 120.90M | 162.75M | 65.71M | 50.57M | -65.45M | 42.54M | 26.76M | 130.93M | 48.01M | -14.89M |
| Net Income Ratio | -0.91% | -0.99% | 1.28% | 11.57% | 11.18% | 10.93% | 37.95% | 18.85% | 12.71% | 15.47% | 16.14% | 14.60% | 20.65% | 24.21% | 28.61% | 24.34% | 36.58% | 31.41% | 40.21% | 51.91% | 79.39% | 33.40% | 24.72% | -27.01% | 18.24% | 17.85% | 4.20% | 1.86% | -0.64% |
| EPS | -0.10 | -0.11 | 0.13 | 1.18 | 1.18 | 1.15 | 3.82 | 1.88 | 1.26 | 1.62 | 1.55 | 1.24 | 1.60 | 1.57 | 1.75 | 1.62 | 2.26 | 1.26 | 1.37 | 1.45 | 2.05 | 0.95 | 0.74 | -0.96 | 0.63 | 0.39 | 1.90 | 0.68 | -0.24 |
| EPS Diluted | -0.10 | -0.11 | 0.13 | 1.17 | 1.17 | 1.14 | 3.78 | 1.86 | 1.25 | 1.60 | 1.54 | 1.23 | 1.58 | 1.56 | 1.74 | 1.62 | 2.25 | 1.25 | 1.36 | 1.43 | 2.03 | 0.93 | 0.73 | -0.96 | 0.63 | 0.39 | 1.86 | 0.68 | -0.21 |
| Weighted Avg Shares Out | 401.81M | 373.37M | 382.79M | 373.37M | 365.98M | 356.27M | 355.33M | 344.70M | 330.31M | 294.18M | 292.65M | 292.06M | 228.45M | 156.61M | 152.57M | 139.57M | 122.60M | 104.21M | 95.04M | 83.49M | 79.34M | 69.34M | 68.41M | 68.01M | 67.75M | 67.68M | 68.94M | 69.70M | 62.32M |
| Weighted Avg Shares Out (Dil) | 401.81M | 373.37M | 386.30M | 376.50M | 369.89M | 359.30M | 358.57M | 348.39M | 334.01M | 296.68M | 295.11M | 294.49M | 230.79M | 157.66M | 152.76M | 139.91M | 123.01M | 104.73M | 95.78M | 84.35M | 80.09M | 70.29M | 69.36M | 68.13M | 67.99M | 68.61M | 70.36M | 70.70M | 71.97M |
Ventas' Tenant Brookdale Opts Out to Exercise Lease Extension
Brookdale Senior Living, a tenant of VTR, chooses not to exercise the extension term of Master Lease.
Brookdale Senior Living Comments on Master Lease with Ventas
NASHVILLE, Tenn. , Dec. 3, 2024 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") confirmed today that it did not exercise its right to renew a master lease with Ventas, Inc. ("Ventas") under the existing lease...
Ventas Comments on Master Lease with Brookdale Senior Living
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today announced that Brookdale Senior Living (“Brookdale”) did not exercise its right to extend the term of the Master Lease between the companies (the “Master Lease”) for a renewal term commencing...
Ventas Earns Nareit 2024 Healthcare “Leader in the Light” Award
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) today announced that it has earned the 2024 Nareit “Leader in the Light” award for the Healthcare sector in recognition of its superior and longstanding sustainability practices. This is the eighth time Ventas has received...
Ventas to Participate in Investor Meetings at Nareit's REITworld 2024 Annual Conference
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) announced today that management will participate in investor meetings at Nareit's REITworld 2024 Annual Conference (the “Nareit Conference”) on November 18-19, 2024. Any new or updated written materials that the Company...
Ventas Announces Pricing of an Underwritten Offering of 10.6 Million Shares of Common Stock
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) announced today that it priced an underwritten public offering of 10,600,000 shares of its common stock in connection with the forward sale agreement described below for gross proceeds of approximately $677...
Ventas Announces Underwritten Offering of 10.6 Million Shares of Common Stock
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) announced today that it is commencing an underwritten public offering of 10,600,000 shares of its common stock in connection with the forward sale agreement described below. Ventas intends to grant the...
Here's Why Ventas Stock is an Apt Portfolio Pick for Now
Rising senior citizens' population and favorable outpatient visit trends are likely to benefit VTR.
Ventas: Growth Set To Continue In The Years Ahead
Ventas is a healthcare REIT focused on senior housing, outpatient medical & research, and triple-net lease properties. The Q3 2024 results were solid and the company increased its normalized FFO midpoint outlook. With a valuation above private market alternatives and...
MOBs, Office But No Need For Life Support
Unlike in traditional office, healthcare requires in-office interactions, which reduces the risk of ‘work from home'. Outpatient services are taking market share from inpatient (hospital) settings due to better costs and, in some cases, outcomes. America's rapidly aging population is...
Source: https://incomestatements.info
Category: Stock Reports